DeepColor offers two complementary product lines built on its proprietary all-optical photoacoustic technology.
For academic and preclinical research, we provide advanced imaging systems tailored to laboratory constraints and designed for high-performance, ease of use, and reliable data acquisition.
For medical device and life sciences companies, DeepColor offers compact imaging modules designed for seamless integration into existing and next-generation products.
Whether you are exploring new research applications or enhancing clinical workflows, let's discuss your project, we'll find the right solution for you.

DeepColor's imaging software suite is continuously evolving to meet the needs of researchers and clinicians alike.
Designed for ease of use, it provides full control over image acquisition, processing, reconstruction, visualization and analysis, with customization options to match your specific workflows.
Our viewer is browser-based and can be used remotely from any PC connected to the same local network

DeepColor develops an all-optical photoacoustic imaging approach leveraging laser-induced ultrasound generation and optical sensing through Fabry–Pérot interferometry for ultrasound detection.

This approach eliminates conventional piezoelectric transducers, enabling improved sensitivity, broadband detection, and highly compact system architectures.

DeepColor's imaging platform addresses clinical needs where established modalities fall short: too invasive, too slow, or lacking the resolution required to guide real-time decisions.

DeepColor's technology is available for OEM integration. We supply both hardware and software, so your team can focus on what it does best while we handle the imaging core. Reach out to discuss how we can accelerate your time-to-market.

DeepColor's technology is backed by over 15 years of peer-reviewed research from the UCL Photoacoustic Imaging Group, one of the most cited groups in the field.

This track record matters. Our technology is not a concept, it is a proven imaging modality with a substantial publication record, independent third-party validation, and demonstrated performance in clinically relevant conditions.

We are bringing a mature and a well-evidenced platform to market.